nach oben

NeuroMolecular Medicine

Erschienen in:

01.06.2010 | Original Paper

The Role of the Complement System and the Activation Fragment C5a in the Central Nervous System

verfasst von: Trent M. Woodruff, Rahasson R. Ager, Andrea J. Tenner, Peter G. Noakes, Stephen M. Taylor

Erschienen in: NeuroMolecular Medicine | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

The complement system is a pivotal component of the innate immune system which protects the host from infection and injury. Complement proteins can be induced in all cell types within the central nervous system (CNS), where the pathway seems to play similar roles in host defense. Complement activation produces the C5 cleavage fragment C5a, a potent inflammatory mediator, which recruits and activates immune cells. The primary cellular receptor for C5a, the C5a receptor (CD88), has been reported to be on all CNS cells, including neurons and glia, suggesting a functional role for C5a in the CNS. A second receptor for C5a, the C5a-like receptor 2 (C5L2), is also expressed on these cells; however, little is currently known about its potential role in the CNS. The potent immune and inflammatory actions of complement activation are necessary for host defense. However, if over-activated, or left unchecked it promotes tissue injury and contributes to brain disease pathology. Thus, complement activation, and subsequent C5a generation, is thought to play a significant role in the progression of CNS disease. Paradoxically, complement may also exert a neuroprotective role in these diseases by aiding in the elimination of aggregated and toxic proteins and debris which are a principal hallmark of many of these diseases. This review will discuss the expression and known roles for complement in the CNS, with a particular focus on the pro-inflammatory end-product, C5a. The possible overarching role for C5a in diseases of the CNS is reviewed, and the therapeutic potential of blocking C5a/CD88 interaction is evaluated.

Afagh, A., Cummings, B. J., Cribbs, D. H., Cotman, C. W., & Tenner, A. J. (1996). Localization and cell association of C1q in Alzheimer’s disease brain. Experimental Neurology, 138, 22–32.PubMed

Akiyama, H., Arai, T., Kondo, H., Tanno, E., Haga, C., & Ikeda, K. (2000). Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Disease and Associated Disorders, 14(Suppl 1), S47–S53.PubMed

Ames, R. S., Li, Y., Sarau, H. M., Nuthulaganti, P., Foley, J. J., Ellis, C., et al. (1996). Molecular cloning and characterization of the human anaphylatoxin C3a receptor. Journal of Biological Chemistry, 271, 20231–20234.PubMed

Armstrong, R. C., Harvath, L., & Dubois-Dalcq, M. E. (1990). Type 1 astrocytes and oligodendrocyte-type 2 astrocyte glial progenitors migrate toward distinct molecules. Journal of Neuroscience Research, 27, 400–407.PubMed

Avery, V. M., Adrian, D. L., & Gordon, D. L. (1993). Detection of mosaic protein mRNA in human astrocytes. Immunology and Cell Biology, 71(Pt 3), 215–219.PubMed

Barnum, S. R., Ishii, Y., Agrawal, A., & Volanakis, J. E. (1992a). Production and interferon-gamma-mediated regulation of complement component C2 and factors B and D by the astroglioma cell line U105-MG. Biochemical Journal, 287(Pt 2), 595–601.PubMed

Barnum, S. R., Jones, J. L., & Benveniste, E. N. (1992b). Interferon-gamma regulation of C3 gene expression in human astroglioma cells. Journal of Neuroimmunology, 38, 275–282.PubMed

Barnum, S. R., Jones, J. L., & Benveniste, E. N. (1993). Interleukin-1 and tumor necrosis factor-mediated regulation of C3 gene expression in human astroglioma cells. Glia, 7, 225–236.PubMed

Benard, M., Gonzalez, B. J., Schouft, M. T., Falluel-Morel, A., Vaudry, D., Chan, P., et al. (2004). Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death. Journal of Biological Chemistry, 279, 43487–43496.PubMed

Benard, M., Raoult, E., Vaudry, D., Leprince, J., Falluel-Morel, A., Gonzalez, B. J., et al. (2008). Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum. Molecular Immunology, 45, 3767–3774.PubMed

Biro, A., Rovo, Z., Papp, D., Cervenak, L., Varga, L., Fust, G., et al. (2007). Studies on the interactions between C-reactive protein and complement proteins. Immunology, 121, 40–50.PubMed

Bohlson, S. S., Fraser, D. A., & Tenner, A. J. (2007). Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Molecular Immunology, 44, 33–43.PubMed

Boos, L., Campbell, I. L., Ames, R., Wetsel, R. A., & Barnum, S. R. (2004). Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. Journal of Immunology, 173, 4708–4714.

Bradt, B. M., Kolb, W. P., & Cooper, N. R. (1998). Complement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide. Journal of Experimental Medicine, 188, 431–438.PubMed

Cain, S. A., & Monk, P. N. (2002). The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). Journal of Biological Chemistry, 277, 7165–7169.PubMed

Chen, N., & Reiss, C. S. (2002). Innate immunity in viral encephalitis: Role of C5. Viral Immunology, 15, 365–372.PubMed

Cole, D. S., Hughes, T. R., Gasque, P., & Morgan, B. P. (2006). Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis. Molecular Immunology, 43, 1953–1964.PubMed

Cowell, R. M., Plane, J. M., & Silverstein, F. S. (2003). Complement activation contributes to hypoxic–ischemic brain injury in neonatal rats. Journal of Neuroscience, 23, 9459–9468.PubMed

Cudrici, C., Niculescu, T., Niculescu, F., Shin, M. L., & Rus, H. (2006). Oligodendrocyte cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement. Journal of Rehabilitation Research and Development, 43, 123–132.PubMed

Daveau, M., Benard, M., Scotte, M., Schouft, M. T., Hiron, M., Francois, A., et al. (2004). Expression of a functional C5a receptor in regenerating hepatocytes and its involvement in a proliferative signaling pathway in rat. Journal of Immunology, 173, 3418–3424.

Davoust, N., Jones, J., Stahel, P. F., Ames, R. S., & Barnum, S. R. (1999). Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia, 26, 201–211.PubMed

Eikelenboom, P., Hack, C. E., Rozemuller, J. M., & Stam, F. C. (1989). Complement activation in amyloid plaques in Alzheimer’s dementia. Virchows Archiv B, Cell Pathology Including Molecular Pathology, 56, 259–262.PubMed

Farkas, I., Baranyi, L., Kaneko, Y., Liposits, Z., Yamamoto, T., & Okada, H. (1999). C5a receptor expression by TGW neuroblastoma cells. Neuroreport, 10, 3021–3025.PubMed

Farkas, I., Baranyi, L., Liposits, Z. S., Yamamoto, T., & Okada, H. (1998). Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells. Neuroscience, 86, 903–911.PubMed

Farkas, I., Takahashi, M., Fukuda, A., Yamamoto, N., Akatsu, H., Baranyi, L., et al. (2003). Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer’s disease. Journal of Immunology, 170, 5764–5771.

Ferraiuolo, L., Heath, P. R., Holden, H., Kasher, P., Kirby, J., & Shaw, P. J. (2007). Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. Journal of Neuroscience, 27, 9201–9219.PubMed

Fonseca, M. I., Ager, R. R., Chu, S. H., Yazan, O., Sanderson, S. D., LaFerla, F. M., et al. (2009). Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer’s disease. Journal of Immunology, 183, 1375–1383.

Fonseca, M. I., Kawas, C. H., Troncoso, J. C., & Tenner, A. J. (2004a). Neuronal localization of C1q in preclinical Alzheimer’s disease. Neurobiology of Diseases, 15, 40–46.

Fonseca, M. I., Zhou, J., Botto, M., & Tenner, A. J. (2004b). Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer’s disease. Journal of Neuroscience, 24, 6457–6465.PubMed

Fukada, Y., Yasui, K., Kitayama, M., Doi, K., Nakano, T., Watanabe, Y., et al. (2007). Gene expression analysis of the murine model of amyotrophic lateral sclerosis: Studies of the Leu126delTT mutation in SOD1. Brain Research, 1160, 1–10.PubMed

Gao, H., Neff, T. A., Guo, R. F., Speyer, C. L., Sarma, J. V., Tomlins, S., et al. (2005). Evidence for a functional role of the second C5a receptor C5L2. FASEB Journal, 19, 1003–1005.PubMed

Garrett, M. C., Otten, M. L., Starke, R. M., Komotar, R. J., Magotti, P., Lambris, J. D., et al.. (2009). Synergistic neuroprotective effects of C3a and C5a receptor blockade following intracerebral hemorrhage. Brain Research.

Gasque, P., Chan, P., Fontaine, M., Ischenko, A., Lamacz, M., Gotze, O., et al. (1995a). Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. Journal of Immunology, 155, 4882–4889.

Gasque, P., Chan, P., Mauger, C., Schouft, M. T., Singhrao, S., Dierich, M. P., et al. (1996b). Identification and characterization of complement C3 receptors on human astrocytes. Journal of Immunology, 156, 2247–2255.

Gasque, P., Dean, Y. D., McGreal, E. P., VanBeek, J., & Morgan, B. P. (2000). Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology, 49, 171–186.PubMed

Gasque, P., Fontaine, M., & Morgan, B. P. (1995b). Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. Journal of Immunology, 154, 4726–4733.

Gasque, P., Ischenko, A., Legoedec, J., Mauger, C., Schouft, M. T., & Fontaine, M. (1993). Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells. Journal of Biological Chemistry, 268, 25068–25074.PubMed

Gasque, P., Julen, N., Ischenko, A. M., Picot, C., Mauger, C., Chauzy, C., et al. (1992). Expression of complement components of the alternative pathway by glioma cell lines. Journal of Immunology, 149, 1381–1387.

Gasque, P., & Morgan, B. P. (1996). Complement regulatory protein expression by a human oligodendrocyte cell line: Cytokine regulation and comparison with astrocytes. Immunology, 89, 338–347.PubMed

Gasque, P., Singhrao, S. K., Neal, J. W., Gotze, O., & Morgan, B. P. (1997). Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. American Journal of Pathology, 150, 31–41.PubMed

Gasque, P., Singhrao, S. K., Neal, J. W., Wang, P., Sayah, S., Fontaine, M., et al. (1998). The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. Journal of Immunology, 160, 3543–3554.

Gasque, P., Thomas, A., Fontaine, M., & Morgan, B. P. (1996a). Complement activation on human neuroblastoma cell lines in vitro: Route of activation and expression of functional complement regulatory proteins. Journal of Neuroimmunology, 66, 29–40.PubMed

Gavrilyuk, V., Kalinin, S., Hilbush, B. S., Middlecamp, A., McGuire, S., Pelligrino, D., et al. (2005). Identification of complement 5a-like receptor (C5L2) from astrocytes: Characterization of anti-inflammatory properties. Journal of Neurochemistry, 92, 1140–1149.PubMed

Gerard, N. P., & Gerard, C. (1991). The chemotactic receptor for human C5a anaphylatoxin. Nature, 349, 614–617.PubMed

Gerard, N. P., Lu, B., Liu, P., Craig, S., Fujiwara, Y., Okinaga, S., et al. (2005). An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. Journal of Biological Chemistry, 280, 39677–39680.PubMed

Gordon, D. L., Avery, V. M., Adrian, D. L., & Sadlon, T. A. (1992a). Detection of complement protein mRNA in human astrocytes by the polymerase chain reaction. Journal of Neuroscience Methods, 45, 191–197.PubMed

Gordon, D. L., Sadlon, T. A., Wesselingh, S. L., Russell, S. M., Johnstone, R. W., & Purcell, D. F. (1992b). Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation. Journal of Neuroimmunology, 36, 199–208.PubMed

Griffin, R. S., Costigan, M., Brenner, G. J., Ma, C. H. E., Scholz, J., Moss, A., et al. (2007). Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. Journal of Neuroscience, 27, 8699–8708.PubMed

Haviland, D. L., McCoy, R. L., Whitehead, W. T., Akama, H., Molmenti, E. P., Brown, A., et al. (1995). Cellular expression of the C5a anaphylatoxin receptor (C5aR): Demonstration of C5aR on nonmyeloid cells of the liver and lung. Journal of Immunology, 154, 1861–1869.

Hosokawa, M., Klegeris, A., Maguire, J., & McGeer, P. L. (2003). Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia, 42, 417–423.PubMed

Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., et al. (2006). Generation of C5a in the absence of C3: A new complement activation pathway. Nature Medicine, 12, 682–687.PubMed

Huber-Lang, M., Younkin, E. M., Sarma, J. V., Riedemann, N., McGuire, S. R., Lu, K. T., et al. (2002). Generation of C5a by phagocytic cells. The American Journal of Pathology, 161, 1849–1859.PubMed

Humayun, S., Gohar, M., Volkening, K., Moisse, K., Leystra-Lantz, C., Mepham, J., et al. (2009). The complement factor C5a receptor is upregulated in NFL^−/− mouse motor neurons. Journal of Neuroimmunology, 210, 52–62.PubMed

Ischenko, A., Sayah, S., Patte, C., Andreev, S., Gasque, P., Schouft, M. T., et al. (1998). Expression of a functional anaphylatoxin C3a receptor by astrocytes. Journal of Neurochemistry, 71, 2487–2496.PubMedCrossRef

Itagaki, S., Akiyama, H., Saito, H., & McGeer, P. L. (1994). Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer’s disease. Brain Research, 645, 78–84.PubMed

Jiang, H., Burdick, D., Glabe, C. G., Cotman, C. W., & Tenner, A. J. (1994). Beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. Journal of Immunology, 152, 5050–5059.

Kim, G. H., Mocco, J., Hahn, D. K., Kellner, C. P., Komotar, R. J., Ducruet, A. F., et al. (2008). Protective effect of C5a receptor inhibition after murine reperfused stroke. Neurosurgery, 63, 122–125; discussion 125–126.PubMed

Kleine, T. O., & Benes, L. (2006). Immune surveillance of the human central nervous system (CNS): Different migration pathways of immune cells through the blood–brain barrier and blood–cerebrospinal fluid barrier in healthy persons. Cytometry A, 69, 147–151.PubMed

Lacy, M., Jones, J., Whittemore, S. R., Haviland, D. L., Wetsel, R. A., & Barnum, S. R. (1995). Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. Journal of Neuroimmunology, 61, 71–78.PubMed

Lee, D. K., George, S. R., Cheng, R., Nguyen, T., Liu, Y., Brown, M., et al. (2001). Identification of four novel human G protein-coupled receptors expressed in the brain. Molecular Brain Research, 86, 13–22.PubMed

Leinhase, I., Holers, V. M., Thurman, J. M., Harhausen, D., Schmidt, O. I., Pietzcker, M., et al. (2006). Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neuroscience, 7, 55.PubMed

Levi-Strauss, M., & Mallat, M. (1987). Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. Journal of Immunology, 139, 2361–2366.

Li, K., Sacks, S. H., & Zhou, W. (2007). The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Molecular Immunology, 44, 3866–3874.PubMed

Liszewski, M. K., Farries, T. C., Lublin, D. M., Rooney, I. A., & Atkinson, J. P. (1996). Control of the complement system. Advances in Immunology, 61, 201–283.PubMed

Lobsiger, C. S., Boillee, S., & Cleveland, D. W. (2007). Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proceedings of the National Academy of Sciences of the United States of America, 104, 7319–7326.PubMed

Loeffler, D. A., Camp, D. M., & Bennett, D. A. (2008). Plaque complement activation and cognitive loss in Alzheimer’s disease. Journal of Neuroinflammation, 5, 9.PubMed

Loos, M., & Clas, F. (1987). Antibody-independent killing of gram-negative bacteria via the classical pathway of complement. Immunology Letters, 14, 203–208.PubMed

Mack, W. J., Ducruet, A. F., Hickman, Z. L., Garrett, M. C., Albert, E. J., Kellner, C. P., et al. (2007). Early plasma complement C3a levels correlate with functional outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery, 61, 255–260; discussion 260–261.PubMed

March, D. R., Proctor, L. M., Stoermer, M. J., Sbaglia, R., Abbenante, G., Reid, R. C., et al. (2004). Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Molecular Pharmacology, 65, 868–879.PubMed

Marjan, J., Xie, Z., & Devine, D. V. (1994). Liposome-induced activation of the classical complement pathway does not require immunoglobulin. Biochimica et Biophysica Acta, 1192, 35–44.PubMed

Mason, J. C., Yarwood, H., Sugars, K., Morgan, B. P., Davies, K. A., & Haskard, D. O. (1999). Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood, 94, 1673–1682.PubMed

Mastellos, D., Germenis, A. E., & Lambris, J. D. (2005). Complement: An inflammatory pathway fulfilling multiple roles at the interface of innate immunity and development. Current Drug Targets. Inflammation and Allergy, 4, 125–127.PubMed

McGeer, P. L., Walker, D. G., Akiyama, H., Kawamata, T., Guan, A. L., Parker, C. J., et al. (1991). Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Research, 544, 315–319.PubMed

Mead, R. J., Singhrao, S. K., Neal, J. W., Lassmann, H., & Morgan, B. P. (2002). The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. Journal of Immunology, 168, 458–465.

Mehlhop, E., & Diamond, M. S. (2006). Protective immune responses against West Nile virus are primed by distinct complement activation pathways. Journal of Experimental Medicine, 203, 1371–1381.PubMed

Miller, A. M., & Stella, N. (2009). Microglial cell migration stimulated by ATP and C5a involve distinct molecular mechanisms: Quantification of migration by a novel near-infrared method. Glia, 57, 875–883.PubMed

Mocco, J., Wilson, D. A., Komotar, R. J., Sughrue, M. E., Coates, K., Sacco, R. L., et al. (2006). Alterations in plasma complement levels after human ischemic stroke. Neurosurgery, 59, 28–33; discussion 28–33.PubMed

Moller, T., Nolte, C., Burger, R., Verkhratsky, A., & Kettenmann, H. (1997). Mechanisms of C5a and C3a complement fragment-induced [Ca²⁺]i signaling in mouse microglia. Journal of Neuroscience, 17, 615–624.PubMed

Morgan, B. P., Griffiths, M., Khanom, H., Taylor, S. M., & Neal, J. W. (2004). Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clinical and Experimental Immunology, 138, 430–438.PubMed

Mukherjee, P., & Pasinetti, G. M. (2000). The role of complement anaphylatoxin C5a in neurodegeneration: Implications in Alzheimer’s disease. Journal of Neuroimmunology, 105, 124–130.PubMed

Mukherjee, P., & Pasinetti, G. M. (2001). Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. Journal of Neurochemistry, 77, 43–49.PubMed

Mukherjee, P., Thomas, S., & Pasinetti, G. M. (2008). Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J Neuroinflammation, 5, 5.PubMed

Muller-Ladner, U., Jones, J. L., Wetsel, R. A., Gay, S., Raine, C. S., & Barnum, S. R. (1996). Enhanced expression of chemotactic receptors in multiple sclerosis lesions. Journal of the Neurological Sciences, 144, 135–141.PubMed

Nataf, S., Davoust, N., & Barnum, S. R. (1998). Kinetics of anaphylatoxin C5a receptor expression during experimental allergic encephalomyelitis. Journal of Neuroimmunology, 91, 147–155.PubMed

Nataf, S., Levison, S. W., & Barnum, S. R. (2001). Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. Brain Research, 894, 321–326.PubMed

Nolte, C., Moller, T., Walter, T., & Kettenmann, H. (1996). Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Neuroscience, 73, 1091–1107.PubMed

Nyakoe, N. K., Taylor, R. P., Makumi, J. N., & Waitumbi, J. N. (2009). Complement consumption in children with Plasmodium falciparum malaria. Malaria Journal, 8, 7.PubMed

O’Barr, S. A., Caguioa, J., Gruol, D., Perkins, G., Ember, J. A., Hugli, T., et al. (2001). Neuronal expression of a functional receptor for the C5a complement activation fragment. Journal of Immunology, 166, 4154–4162.

O’Barr, S., Yu, J. X., & Cooper, N. R. (1998). Neuronal expression of the C5a receptor. Molecular Immunology, 35, 26.

Ohno, M., Hirata, T., Enomoto, M., Araki, T., Ishimaru, H., & Takahashi, T. A. (2000). A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Molecular Immunology, 37, 407–412.PubMed

Osaka, H., McGinty, A., Hoepken, U. E., Lu, B., Gerard, C., & Pasinetti, G. M. (1999a). Expression of C5a receptor in mouse brain: Role in signal transduction and neurodegeneration. Neuroscience, 88, 1073–1082.PubMed

Osaka, H., Mukherjee, P., Aisen, P. S., & Pasinetti, G. M. (1999b). Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. Journal of Cellular Biochemistry, 73, 303–311.PubMed

Otto, M., Hawlisch, H., Monk, P. N., Muller, M., Klos, A., Karp, C. L., et al. (2004). C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: Position 69 is the locus that determines agonism or antagonism. Journal of Biological Chemistry, 279, 142–151.PubMed

Patel, S. N., Berghout, J., Lovegrove, F. E., Ayi, K., Conroy, A., Serghides, L., et al. (2008). C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. Journal of Experimental Medicine, 205, 1133–1143.PubMed

Peitsch, M. C., Tschopp, J., Kress, A., & Isliker, H. (1988). Antibody-independent activation of the complement system by mitochondria is mediated by cardiolipin. Biochemical Journal, 249, 495–500.PubMed

Persson, M., Pekna, M., Hansson, E., & Ronnback, L. (2009). The complement-derived anaphylatoxin C5a increases microglial GLT-1 expression and glutamate uptake in a TNF-alpha-independent manner. European Journal of Neuroscience, 29, 267–274.PubMed

Pisalyaput, K., & Tenner, A. J. (2008). Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. Journal of Neurochemistry, 104, 696–707.PubMed

Podack, E. R., Tschoop, J., & Muller-Eberhard, H. J. (1982). Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b–8 assembly. Journal of Experimental Medicine, 156, 268–282.PubMed

Rahpeymai, Y., Hietala, M. A., Wilhelmsson, U., Fotheringham, A., Davies, I., Nilsson, A. K., et al. (2006). Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO Journal, 25, 1364–1374.PubMed

Reiman, R., Campos Torres, A., Martin, B. K., Ting, J. P., Campbell, I. L., & Barnum, S. R. (2005). Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis. Neuroscience Letters, 390, 134–138.PubMed

Reiman, R., Gerard, C., Campbell, I. L., & Barnum, S. R. (2002). Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis. European Journal of Immunology, 32, 1157–1163.PubMed

Ricklin, D., & Lambris, J. D. (2007). Complement-targeted therapeutics. Nature Biotechnology, 25, 1265–1275.PubMed

Rittirsch, D., Flierl, M. A., Nadeau, B. A., Day, D. E., Huber-Lang, M., Mackay, C. R., et al. (2008). Functional roles for C5a receptors in sepsis. Nature Medicine, 14, 551–557.PubMed

Roestenberg, M., McCall, M., Mollnes, T. E., van Deuren, M., Sprong, T., Klasen, I., et al. (2007). Complement activation in experimental human malaria infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 101, 643–649.PubMed

Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007). Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnology, 25, 1256–1264.PubMed

Rus, H., Cudrici, C., & Niculescu, F. (2005). C5b–9 complement complex in autoimmune demyelination and multiple sclerosis: Dual role in neuroinflammation and neuroprotection. Annals of Medicine, 37, 97–104.PubMed

Sayah, S., Ischenko, A. M., Zhakhov, A., Bonnard, A. S., & Fontaine, M. (1999). Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: Specific increase in interleukin-6 mRNA expression. Journal of Neurochemistry, 72, 2426–2436.PubMed

Schieferdecker, H. L., Rothermel, E., Timmermann, A., Gotze, O., & Jungermann, K. (1997). Anaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liver. FEBS Letters, 406, 305–309.PubMed

Scolding, N. J., Morgan, B. P., & Compston, D. A. (1998). The expression of complement regulatory proteins by adult human oligodendrocytes. Journal of Neuroimmunology, 84, 69–75.PubMed

Sewell, D. L., Nacewicz, B., Liu, F., Macvilay, S., Erdei, A., Lambris, J. D., et al. (2004). Complement C3 and C5 play critical roles in traumatic brain cryoinjury: Blocking effects on neutrophil extravasation by C5a receptor antagonist. Journal of Neuroimmunology, 155, 55–63.PubMed

Shen, Y., Lue, L., Yang, L., Roher, A., Kuo, Y., Strohmeyer, R., et al. (2001). Complement activation by neurofibrillary tangles in Alzheimer’s disease. Neuroscience Letters, 305, 165–168.PubMed

Singhrao, S. K., Neal, J. W., Morgan, B. P., & Gasque, P. (1999). Increased complement biosynthesis by microglia and complement activation on neurons in Huntington’s disease. Experimental Neurology, 159, 362–376.PubMed

Singhrao, S. K., Neal, J. W., Rushmere, N. K., Morgan, B. P., & Gasque, P. (2000). Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. The American Journal of Pathology, 157, 905–918.PubMed

Stahel, P. F., & Barnum, S. R. (1997). Bacterial meningitis: Complement gene expression in the central nervous system. Immunopharmacology, 38, 65–72.PubMed

Stahel, P. F., Frei, K., Eugster, H. P., Fontana, A., Hummel, K. M., Wetsel, R. A., et al. (1997a). TNF-alpha-mediated expression of the receptor for anaphylatoxin C5a on neurons in experimental Listeria meningoencephalitis. Journal of Immunology, 159, 861–869.

Stahel, P. F., Kariya, K., Shohami, E., Barnum, S. R., Eugster, H., Trentz, O., et al. (2000). Intracerebral complement C5a receptor (CD88) expression is regulated by TNF and lymphotoxin-alpha following closed head injury in mice. Journal of Neuroimmunology, 109, 164–172.PubMed

Stahel, P. F., Kossmann, T., Morganti-Kossmann, M. C., Hans, V. H., & Barnum, S. R. (1997b). Experimental diffuse axonal injury induces enhanced neuronal C5a receptor mRNA expression in rats. Molecular Brain Research, 50, 205–212.PubMed

Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., et al. (2007). The classical complement cascade mediates CNS synapse elimination. Cell, 131, 1164–1178.PubMed

Storrs, S. B., Kolb, W. P., & Olson, M. S. (1983). C1q binding and C1 activation by various isolated cellular membranes. Journal of Immunology, 131, 416–422.

Tenner, A. J., Ziccardi, R. J., & Cooper, N. R. (1984). Antibody-independent C1 activation by E. coli. Journal of Immunology, 133, 886–891.

Thomas, A., Gasque, P., Vaudry, D., Gonzalez, B., & Fontaine, M. (2000). Expression of a complete and functional complement system by human neuronal cells in vitro. International Immunology, 12, 1015–1023.PubMed

Van Beek, J., Bernaudin, M., Petit, E., Gasque, P., Nouvelot, A., MacKenzie, E. T., et al. (2000). Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Experimental Neurology, 161, 373–382.PubMed

Van Beek, J., Elward, K., & Gasque, P. (2003). Activation of complement in the central nervous system: Roles in neurodegeneration and neuroprotection. Annals of the New York Academy of Sciences, 992, 56–71.PubMed

Van Beek, J., van Meurs, M., t Hart, B. A., Brok, H. P., Neal, J. W., Chatagner, A., et al. (2005). Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. Journal of Immunology, 174, 2353–2365.

Veerhuis, R., Janssen, I., De Groot, C. J., Van Muiswinkel, F. L., Hack, C. E., & Eikelenboom, P. (1999). Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Experimental Neurology, 160, 289–299.

Veerhuis, R., Janssen, I., Hoozemans, J. J., De Groot, C. J., Hack, C. E., & Eikelenboom, P. (1998). Complement C1-inhibitor expression in Alzheimer’s disease. Acta Neuropathologica, 96, 287–296.PubMed

Vergunst, C. E., Gerlag, D. M., Dinant, H., Schulz, L., Vinkenoog, M., Smeets, T. J., et al. (2007). Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford), 46, 1773–1778.

Walker, D. G., Kim, S. U., & McGeer, P. L. (1995a). Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. Journal of Neuroscience Research, 40, 478–493.PubMed

Walker, D. G., Kim, S. U., & McGeer, P. L. (1998). Expression of complement C4 and C9 genes by human astrocytes. Brain Research, 809, 31–38.PubMed

Walker, D. G., & McGeer, P. L. (1992). Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Molecular Brain Research, 14, 109–116.PubMed

Walker, D. G., & McGeer, P. L. (1993). Complement gene expression in neuroblastoma and astrocytoma cell lines of human origin. Neuroscience Letters, 157, 99–102.PubMed

Walker, D. G., Yasuhara, O., Patston, P. A., McGeer, E. G., & McGeer, P. L. (1995b). Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Research, 675, 75–82.PubMed

Webster, S., Lue, L. F., Brachova, L., Tenner, A. J., McGeer, P. L., Terai, K., et al. (1997). Molecular and cellular characterization of the membrane attack complex, C5b–9, in Alzheimer’s disease. Neurobiology of Aging, 18, 415–421.PubMed

Woodruff, T. M., Costantini, K. J., Crane, J. W., Atkin, J. D., Monk, P. N., Taylor, S. M., et al. (2008a). The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. Journal of Immunology, 181, 8727–8734.

Woodruff, T. M., Costantini, K. J., Taylor, S. M., & Noakes, P. G. (2008b). Role of complement in motor neuron disease: Animal models and therapeutic potential of complement inhibitors. Advances in Experimental Medicine and Biology, 632, 143–158.PubMed

Woodruff, T. M., Crane, J. W., Proctor, L. M., Buller, K. M., Shek, A. B., de Vos, K., et al. (2006a). Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB Journal, 20, 1407–1417.PubMed

Woodruff, T. M., Pollitt, S., Proctor, L. M., Stocks, S. Z., Manthey, H. D., Williams, H. M., et al. (2005). Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. Journal of Pharmacology and Experimental Therapeutics, 314, 811–817.PubMed

Woodruff, T. M., Proctor, L. M., Strachan, A. J., & Taylor, S. M. (2006b). Complement factor 5a as a therapeutic target. Drug Future, 31, 325–334.

Woodruff, T. M., Strachan, A. J., Dryburgh, N., Shiels, I. A., Reid, R. C., Fairlie, D. P., et al. (2002). Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis and Rheumatism, 46, 2476–2485.PubMed

Xi, G., Hua, Y., Keep, R. F., Younger, J. G., & Hoff, J. T. (2001). Systemic complement depletion diminishes perihematomal brain edema in rats. Stroke, 32, 162–167.PubMed

Yang, C., Jones, J. L., & Barnum, S. R. (1993). Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. Journal of Neuroimmunology, 47, 123–132.PubMed

Yao, J., Harvath, L., Gilbert, D. L., & Colton, C. A. (1990). Chemotaxis by a CNS macrophage, the microglia. Journal of Neuroscience Research, 27, 36–42.PubMed

Zajicek, J., Wing, M., Skepper, J., & Compston, A. (1995). Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system. Laboratory Investigation, 73, 128–138.PubMed

Zhou, J., Fonseca, M. I., Pisalyaput, K., & Tenner, A. J. (2008). Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease. Journal of Neurochemistry, 106, 2080–2092.PubMed

Titel: The Role of the Complement System and the Activation Fragment C5a in the Central Nervous System
verfasst von: Trent M. Woodruff
Rahasson R. Ager
Andrea J. Tenner
Peter G. Noakes
Stephen M. Taylor
Publikationsdatum: 01.06.2010
Verlag: Humana Press Inc
Erschienen in: NeuroMolecular Medicine / Ausgabe 2/2010
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-009-8085-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The Role of the Complement System and the Activation Fragment C5a in the Central Nervous System

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Leukocyte Recruitment and Ischemic Brain Injury

Involvement of Fc Receptors in Disorders of the Central Nervous System

Phospholipases A2 and Inflammatory Responses in the Central Nervous System

Role of Cytokines as Mediators and Regulators of Microglial Activity in Inflammatory Demyelination of the CNS

A Clear and Present Danger: Endogenous Ligands of Toll-like Receptors

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie